Rational polynomial representation of ribonucleotide reductase activity
 Tomas Radivoyevitch^{1}Email author,
 Ossama B Kashlan^{2} and
 Barry S Cooperman^{3}
DOI: 10.1186/1471209168
© Radivoyevitch et al; licensee BioMed Central Ltd. 2005
Received: 29 December 2004
Accepted: 06 May 2005
Published: 06 May 2005
Abstract
Background
Recent data suggest that ribonucleotide reductase (RNR) exists not only as a heterodimer R1_{2}R2_{2} of R1_{2} and R2_{2} homodimers, but also as tetramers R1_{4}R2_{4} and hexamers R1_{6}R2_{6}. Recent data also suggest that ATP binds the R1 subunit at a previously undescribed hexamerization site, in addition to its binding to previously described dimerization and tetramerization sites. Thus, the current view is that R1 has four NDP substrate binding possibilities, four dimerization site binding possibilities (dATP, ATP, dGTP, or dTTP), two tetramerization site binding possibilities (dATP or ATP), and one hexamerization site binding possibility (ATP), in addition to possibilities of unbound site states. This large number of internal R1 states implies an even larger number of quaternary states. A mathematical model of RNR activity which explicitly represents the states of R1 currently exists, but it is complicated in several ways: (1) it includes up to sixfold nested sums; (2) it uses different mathematical structures under different substratemodulator conditions; and (3) it requires root solutions of high order polynomials to determine R1 proportions in mono, di, tetra and hexamer states and thus RNR activity as a function of modulator and total R1 concentrations.
Results
We present four (one for each NDP) rational polynomial models of RNR activity as a function of substrate and reaction rate modifier concentrations. The new models avoid the complications of the earlier model without compromising curve fits to recent data.
Conclusion
Compared to the earlier model of recent data, the new rational polynomial models are simpler, adequately fitting, and likely better suited for biochemical network simulations.
Background
Ribonucleotide reductase (RNR) is a key component of de novo deoxynucleotide (dNTP) metabolism and an important target of cancer therapies [1]. This enzyme, which reduces ribonucleoside diphosphates into corresponding deoxyribonucleoside diphosphates, is exquisitely controlled to properly balance dNTP fluxes in the face of changing scheduled (S phase) and unscheduled (DNA damage/repair) dNTP synthesis demands [2].
Results
Reaction activities are viewed here as weighted sums of enzyme state specific activities multiplied by probabilities of enzymes being in specific states. For example, a MichaelisMenten reaction rate law is viewed as
where the probability that the enzyme is in a loaded/reactive state (with activity k_{cat}) is P(EA) and the probability that the enzyme is in an empty/unreactive state (with no activity) is P(E).
The RNR models presented here are based on the following four enzyme state probability assumptions:
2. The probability that L ∈ {ATP, dATP, dTTP, dGTP} is also bound to the dimerization/specificity site, conditional on NDP binding, is assumed to be
where, if L = dTTP and NDP = GDP for example,
is the probability that dTTP is bound to the dimerization/specificity site given that GDP is bound to the substrate site; the probability of an empty dimerization/specificity site is thus
3. The probability that the tetramerization site is either empty, occupied by ATP, or occupied by dATP, is assumed to be, respectively,
4. Finally, the probability that the hexamerization site is occupied by ATP is assumed to be
Parameter estimates of the reductase models. Fits to data are as shown in Figure 2.
substrate  K_{sdATP}  K_{sATP}  K_{sdTTP}  K_{sdGTP}  K_{idATP}  K_{iATP}  K_{aATP}  k_{2}  k_{2dA}  k_{2A}  k_{2e}  k_{4}  k_{6} 

ADP  2  200  2.4^{b}  0.5  1.25  300  2000^{d}  0.21  0.03  0.16  
GDP  1  100  0.5  2  2  190  2400  0.28^{a}  0.04  0.19  
CDP  2  70  1.55^{b}  2^{c}  1.5  600  1400  0.25^{a}  0.29^{a}  0.08  0.32  
UDP  1  100  0.7^{b}  2^{c}  0.5  200  800  0.26  0.26  0.26^{a} 
Previous work [3–6] has shown that the dimer and hexamer states are active, that the tetramer state is slightly active for ADP and GDP and is otherwise inactive, that dimer state activity for CDP and UDP exists when ATP or dATP is bound to the dimerization/specificity site, and that an empty dimerization/specificity site still permits the formation of some dimer with CDP reductase activity, see Table 5 of [5]. Thus, based on the enzyme state probabilities given above, for k_{cat} implicitly defined through
we propose the following expressions:
ADP reduction
GDP reduction
CDP reduction
UDP reduction
Discussion
In general, when an integrated system is engineered from component subsystems, the behavior of the overall system depends on component inputoutput specifications more so than the details of component implementations. By analogy, when enzymological data are applied to biochemical network modeling, rather than the elucidation of reaction mechanisms, it can be expected that the reaction surfaces themselves (i.e. the enzyme's inputoutput characteristics) determine network behavior more so than the details of how such surfaces are represented. Thus, for applications to systems biology, large confidence intervals (CI) in the model parameter estimates of Table 1 (not shown) are not a problem because only goodnessoffit (Fig. 2) really matters; this claim assumes an operating range within the data range, since similarly fitting models often veer apart when used in extrapolations. If reaction mechanism inferences were instead being sought, the large CI in the model parameter estimates would have been a problem, e.g. the squared terms in the model suggest cooperative binding, but this choice provides only slightly better curve fits compared to linear terms (not shown), so cooperative binding cannot be inferred from this model.
Conclusion
We identified a rational polynomial model of RNR activity that has single algebraic expressions for each reductase reaction rate law. The expressions provide reasonably good fits (Fig. 2) to recent data [3–6]. Compared to previous reaction rate expressions for this data [3–6], the new expressions are simpler and thus better suited for biochemical network simulations, particularly those constrained to use enzyme reaction rate laws defined as single algebraic expressions [11, 12].
Methods
The parameter estimates shown in Table 1 were obtained through a trialanderror iterative process of nonlinear least squares curve fitting under various, convergence enabling, parameter fixations (i.e. profile searches). In the end, the curve fits were those of Figure 2 with corresponding parameter estimates in Table 1; large 95% confidence intervals (not shown) allowed rounding of the parameter estimates to somewhat arbitrary choices. Nonlinear least squares parameter estimations were performed using the optimization method of Nelder and Mead [13] and the statistical computing environment R [14]. All parameters were estimated as e^{c} to assure positive values. For additional details, R scripts are available with the data as supplementary material [15].
List of abbreviations
 RNR:

= ribonucleotide reductase
 dNTP:

= deoxynucleoside tripshospate
 dNDP:

= deoxynucleoside dipshospate
 a :

= activation
 i :

= inactivation
 s :

= specificity
 h :

= hexamerization
 t :

= tetramerization
 d :

= dimerization
 CI:

= confidence interval
 SBML:

= Systems Biology Markup Language.
Declarations
Acknowledgements
We thank Dr. Charles Scott for sharing his data. TR was supported by the Biostatistics Core Facility of the Comprehensive Cancer Center of Case Western Reserve University and University Hospitals of Cleveland (P30 CA43703), the American Cancer Society (IRG9102209), the National Cancer Institute's Integrative Cancer Biology Program (P20 CA11296301) and NIH grant 1K25 CA10479101A1. BSC was supported by NIH grant CA 58567. OBK was a recipient of a postdoctoral fellowship award from the PennsylvaniaDelaware Affiliate of the AHA, and was supported by grants DK061296 and DK066883 from the NIH.
Authors’ Affiliations
References
 Tsimberidou AM, Alvarado Y, Giles FJ: Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. Expert Rev Anticancer Ther. 2002, 2 (4): 437448. 10.1586/14737140.2.4.437.View ArticlePubMedGoogle Scholar
 Kolberg M, Strand KR, Graff P, Andersson KK: Structure, function, and mechanism of ribonucleotide reductases. Biochim Biophys Acta. 2004, 1699 (12): 134.View ArticlePubMedGoogle Scholar
 Cooperman BS, Kashlan OB: A comprehensive model for the allosteric regulation of Class Ia ribonucleotide reductases. Adv Enzyme Regul. 2003, 43: 167182. 10.1016/S00652571(02)000353.View ArticlePubMedGoogle Scholar
 Kashlan OB, Cooperman BS: Comprehensive model for allosteric regulation of mammalian ribonucleotide reductase: refinements and consequences. Biochemistry. 2003, 42 (6): 16961706. 10.1021/bi020634d.View ArticlePubMedGoogle Scholar
 Kashlan OB, Scott CP, Lear JD, Cooperman BS: A comprehensive model for the allosteric regulation of mammalian ribonucleotide reductase. Functional consequences of ATP and dATPinduced oligomerization of the large subunit. Biochemistry. 2002, 41 (2): 462474. 10.1021/bi011653a.View ArticlePubMedGoogle Scholar
 Scott CP, Kashlan OB, Lear JD, Cooperman BS: A quantitative model for allosteric control of purine reduction by murine ribonucleotide reductase. Biochemistry. 2001, 40 (6): 16511661. 10.1021/bi002335z.View ArticlePubMedGoogle Scholar
 Jackson RC: The Theoretical Foundations of Cancer Chemotherapy Introduced by Computer Models. 1992, New York , Academic Press, 447Google Scholar
 Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, Arkin AP, Bornstein BJ, Bray D, CornishBowden A, Cuellar AA, Dronov S, Gilles ED, Ginkel M, Gor V, Goryanin II, Hedley WJ, Hodgman TC, Hofmeyr JH, Hunter PJ, Juty NS, Kasberger JL, Kremling A, Kummer U, Le Novere N, Loew LM, Lucio D, Mendes P, Minch E, Mjolsness ED, Nakayama Y, Nelson MR, Nielsen PF, Sakurada T, Schaff JC, Shapiro BE, Shimizu TS, Spence HD, Stelling J, Takahashi K, Tomita M, Wagner J, Wang J: The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics. 2003, 19 (4): 524531. 10.1093/bioinformatics/btg015.View ArticlePubMedGoogle Scholar
 Finney A, Hucka M: Systems biology markup language: Level 2 and beyond. Biochem Soc Trans. 2003, 31 (Pt 6): 14721473.View ArticlePubMedGoogle Scholar
 Systems Biology Markup Language. [http://sbml.org]
 Radivoyevitch T: A twoway interface between limited Systems Biology Markup Language and R. BMC Bioinformatics. 2004, 5 (1): 19010.1186/147121055190.PubMed CentralView ArticlePubMedGoogle Scholar
 Radivoyevitch T: SBMLR. [http://www.bioconductor.org/repository/devel/package/html/SBMLR.html]
 Nelder JA, Mead R: A simplex algorithm for function minimization. Computer Journal. 1965, 7: 308313.View ArticleGoogle Scholar
 Ihaka R, Gentleman R: R:a language for data analysis and graphics. Journal of Computational and graphical statistics. 1996, 5: 299314.Google Scholar
 Radivoyevitch T, Kashlan OB, Cooperman BS: Rational Polynomial Representation of Ribonucleotide Reductase Activity. [http://epbiradivot.cwru.edu/cooperman/]
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.